Chen J M, Gao H Y, Wang Q, Li Q
Clin Exp Obstet Gynecol. 2016;43(3):397-400.
CA19-9, CA125, AFP, CEA, and CA153 are common cancer biomarkers. This study aimed to detect the expression and assess clinical significance of these biomarkers in ovarian mature cystic teratomas (OMCT).
The clinical data of 312 resected patients with ovarian mature cystic teratoma referred to the third Hospital of Suzhou University from January 2008 to February 2014 were analyzed retrospectively. Levels of serum CA19-9, CA125, CA153, AFP, and CEA were detected.
Levels of serum CA19-9, CA125, AFP, and CEA were detected in all patients, but the level of serum CA153 was detected in 36 patients. The positive expression of these biomarkers above is 45.83%, 6.09%, 0.00%, 0.64%, and 2.78%, respectively. Ovarian tumor diameter in CA19-9 and CA 125 elevation is larger than that in negative group. The levels of serum CA19-9 and CA125 in multilocular ovarian tumor patients is higher than that in unilocular ovarian tumor patients. The level of serum CA19-9 in bilateral ovarian tumor patients is higher than that in unilateral patients. The level of CA19-9 in patients three months after operation decreased significantly compared with that before operation.
The present study suggests that elevated CA 19-9 is probably the most reliable marker among many tumor markers in the OMCT. It is valuable for diagnosis and recurrence of OMCT.
CA19-9、CA125、甲胎蛋白(AFP)、癌胚抗原(CEA)和CA153是常见的癌症生物标志物。本研究旨在检测这些生物标志物在卵巢成熟囊性畸胎瘤(OMCT)中的表达并评估其临床意义。
回顾性分析2008年1月至2014年2月苏州大学附属第三医院收治的312例行卵巢成熟囊性畸胎瘤切除术患者的临床资料。检测血清CA19-9、CA125、CA153、AFP和CEA水平。
所有患者均检测了血清CA19-9、CA125、AFP和CEA水平,36例患者检测了血清CA153水平。上述生物标志物的阳性表达率分别为45.83%、6.09%、0.00%、0.64%和2.78%。CA19-9和CA125升高患者的卵巢肿瘤直径大于阴性组。多房性卵巢肿瘤患者血清CA19-9和CA125水平高于单房性卵巢肿瘤患者。双侧卵巢肿瘤患者血清CA19-9水平高于单侧患者。术后3个月患者的CA19-9水平较术前显著下降。
本研究表明,CA19-9升高可能是OMCT众多肿瘤标志物中最可靠的标志物。它对OMCT的诊断和复发具有重要价值。